Replacing procarbazine with etoposide in a new OEPA/COPE treatment scheme in children and adolescents with Hodgkin lymphoma: An evaluation of outcomes in the National Cancer Institute
Keywords:
Hodgkin’s lymphoma, Children, TreatmentAbstract
Purpose: Hodgkin’s lymphoma (HL) has an age-standardised incidence of 5.3 cases per 100,000 population, and a cure rate of over 90% of cases. The prognosis depends on multiple factors, the most relevant being: stage, histological type and prognostic indices. It was decided to characterise and evaluate survival outcomes of patients treated with HL in the National Cancer Institute.
Patients and methods: A retrospective analysis was performed on a cohort of patients younger than 19 years diagnosed with HL between January 1, 2000 and December 31, 2005, treated in the National Cancer Institute, with emphasis on their demographic, clinical, histopathological, and laboratory characteristics. A descriptive statistical and survival analysis was performed using the Kaplan-Meier log-rank test. A P<.05 was considered statistically significant.
Results: The mean follow-up time was 5 years (range: 19 months -1 1 .6 years), and overall and disease-free survival was 95% and 83%, respectively, at 5 years.
Conclusion: Implementation of an OEPA/COPE treatment protocol in the National Cancer Institute showed good results, as reflected in overall and disease -free survival, exceeding 80%.
Author Biographies
John Lopera Marín, Instituto Nacional de Cancerología
Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Amaranto Suárez Mattos, Instituto Nacional de Cancerología
Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Oscar Gamboa, Instituto Nacional de Cancerología
Subdirección de investigación, vigilancia epidemiológica, promoción y prevención, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Martha Piña Quintero, Instituto Nacional de Cancerología
Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Gretti Terselich, Instituto Nacional de Cancerología
Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
References
Scheuer ME, Bondy ML, Gumey JG. Epidemiology of chilhood cancer. En: Pizzo PA, Poplack DG, editores. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott- Williams a Wilkkins; 2011. p. 2-13.
Reiter A, Ferrando A. Malignant lymphomas and lymphadeno- pathies. En: Orkin S, Fisher D, Look AT, Lux S, Ginsburg D, Nathan DG, editores. Oncology of infancy and childhood. Philadelphia: Saunders Elsevier; 2009. p. 417-505.
https://doi.org/10.1016/B978-1-4160-3431-5.00013-3
Bravo LE, Collazos T, García LS, Gutiérrez A, Carrascal E. Cáncer infantil en Cali, Colombia 1994-2003. Registro Poblacional de Cáncer en Cali, 2009. Cali, Colombia: Catorse; 2009.
Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Weinstein H, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol. 2003;21(10):2026-33.
https://doi.org/10.1200/JCO.2003.07.124
Schellong G, Brámswig JH, Hbrning-Franz I. Treatment of children with Hodgkin's disease - results of the German Pediatric Oncology Group. Ann Oncol. 1992;3 Suppl 4:73-6.
https://doi.org/10.1093/annonc/3.suppl_4.S73
Schellong G, Potter R, Brámswig J, Wagner W, Prott FJ, Dbrffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian Multicenter Trial DAL-HD 90. J Clin Oncol. 1999;17(12): 3736-44.
https://doi.org/10.1200/JCO.1999.17.12.3736
Lukes RJ, Craver L, Hall TC. Report of the nomenclature committee. Cancer Res. 1966;26:1311.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1.
Cabrera ME, García H, Lois V, León A, Peña K, Rossle A, et al. Linfoma de Hodgkin en Chile. Experiencia de 15 años del Programa Nacional de Cáncer del Adulto. Rev Méd Chile. 2007; 135(3): 341-50.
https://doi.org/10.4067/S0034-98872007000300009
Padilla JJ, Ulloa V, Venegas D. Características epidemiológicas, clínicas y patológicas de los linfomas en el Hospital Nacional Cayetano Heredia del año 1998 al 2008. Acta Med Per. 2011;28(1):12-6.
Quero-Hemández A, Álvarez-Solís RM, Vargas-Vallejo M, Ellis- Irigoyen A, Fenton NP, Tenorio-Rodríguez H, et al. Tratamiento de niños con enfermedad de Hodgkin usando el esquema COP- AVBD. Rev Mex Pediatr. 2009;76(4):165-9.
Dbrffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Par- waresch R, et al. Preliminary results of the multicenter trial GPOH HD-95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr. 2003;215(3):139-45.
https://doi.org/10.1055/s-2003-39372
Schellong G. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German- Austrian Study-Group since 1978. Ann Oncol. 1996;7 Suppl 4:67-72.
https://doi.org/10.1093/annonc/7.suppl_4.S67
Fox J, Terselich G, Suárez A, Saavedra C. Evaluación del tratamiento OPPA/COPP y/o radioterapia en menores de 18 años con linfoma de Hodgkin en el Instituto Nacional de Cancero- logia, Colombia entre 1988-1998. Tesis de grado para obtener título de Oncólogo Pediatra. 2003; Biblioteca INC.
Pinkerton E, Pinkerton R. Hodgkin Disease. In: Pinkerton R, Shankar AG, Matthay K, editores, Evidence Based Pediatric Oncology. 2ed. Blackwell Publishing. BMJ/Books; 2007.199-219.
https://doi.org/10.1002/9780470987148
Larraín C, Cuchacovich M, Conte G. Efecto de la quimioterapia C-MOPP en enfermedad de Hodgkin en etapas NIB y IVB. Rev Med Chile. 1987;115:842-6.
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21): 1478-84.
https://doi.org/10.1056/NEJM199211193272102
Howard SC, Metzger ML, Hudson MM. Linfoma de Hodgkin. En: Sierrasesúmaga L, Antillón F, editores. Tratado de oncología pediátrica. Madrid: Ed. Pearson educación; 2006. p. 365-99.
Jenkin D, Doyle J, Berry M, Blanchette V, Chan H, Doherty M, et al. Hodgkin's disease in children: treatment with MOPP and low-dose, extended field irradiation without laparotomy. Late results and toxicity. Med pediatric Oncol. 1990;18:265-72.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |